173 related articles for article (PubMed ID: 11349086)
1. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans.
Jertborn M; Nordström I; Kilander A; Czerkinsky C; Holmgren J
Infect Immun; 2001 Jun; 69(6):4125-8. PubMed ID: 11349086
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
3. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.
Kozlowski PA; Williams SB; Lynch RM; Flanigan TP; Patterson RR; Cu-Uvin S; Neutra MR
J Immunol; 2002 Jul; 169(1):566-74. PubMed ID: 12077289
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.
Wassen L; Jertborn M
Clin Diagn Lab Immunol; 2005 Mar; 12(3):447-52. PubMed ID: 15753258
[TBL] [Abstract][Full Text] [Related]
5. Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans.
Wassen L; Jertborn M
Clin Vaccine Immunol; 2006 Feb; 13(2):202-7. PubMed ID: 16467326
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
7. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity.
Nochi T; Yuki Y; Katakai Y; Shibata H; Tokuhara D; Mejima M; Kurokawa S; Takahashi Y; Nakanishi U; Ono F; Mimuro H; Sasakawa C; Takaiwa F; Terao K; Kiyono H
J Immunol; 2009 Nov; 183(10):6538-44. PubMed ID: 19880451
[TBL] [Abstract][Full Text] [Related]
8. The roles of mesoporous silica and carbon nanoparticles in antigen stability and intensity of immune response against recombinant subunit B of cholera toxin in a rabbit animal model.
Karimi Bavandpour A; Bakhshi B; Najar-Peerayeh S
Int J Pharm; 2020 Jan; 573():118868. PubMed ID: 31765785
[TBL] [Abstract][Full Text] [Related]
9. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
10. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.
Johansson EL; Rask C; Fredriksson M; Eriksson K; Czerkinsky C; Holmgren J
Infect Immun; 1998 Feb; 66(2):514-20. PubMed ID: 9453604
[TBL] [Abstract][Full Text] [Related]
11. Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.
Jertborn M; Svennerholm AM; Holmgren J
Vaccine; 1994 Sep; 12(12):1078-82. PubMed ID: 7998416
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
Xu G; Wang S; Zhuang L; Hackett A; Gu L; Zhang L; Zhang C; Wang H; Huang Z; Lu S
Vaccine; 2009 Jun; 27(29):3821-30. PubMed ID: 19443090
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach.
Johansson EL; Bergquist C; Edebo A; Johansson C; Svennerholm AM
Vaccine; 2004 Feb; 22(8):984-90. PubMed ID: 15161075
[TBL] [Abstract][Full Text] [Related]
14. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
15. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
Boustanshenas M; Bakhshi B; Ghorbani M
J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
[TBL] [Abstract][Full Text] [Related]
16. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
Carrada Bravo T
Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024
[TBL] [Abstract][Full Text] [Related]
17. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
18. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
Jertborn M; Svennerholm AM; Holmgren J
Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.
Rudin A; Riise GC; Holmgren J
Infect Immun; 1999 Jun; 67(6):2884-90. PubMed ID: 10338495
[TBL] [Abstract][Full Text] [Related]
20. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
Yu X; Ma Q
Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
